

Measles IgM Capture EIA

BluePoint Bioscience, LLC is proud to announce a distribution agreement with Microimmune, Limited. U.K. Microimmune is a leading manufacturer of kits for the serological diagnosis and surveillance of vaccine-preventable diseases. Microimmune produces kits for in-vitro diagnostic use in the detection of IgG and IgM antibodies to mumps and measles virus in human serum and plasma.

Kit Features

- * Assay time < 2 hours
- * Specimen type: serum/plasma
- * Reagents: Color coded and mostly ready to use
- * No sample pretreatment other than dilution
- * Shelf life: 12 months at 2-8 degrees Celsius
- * Sensitivity: 100% on serum specimens compared to an IgM capture radioimmunoassay (MACRIA)
- * Specificity: 96.1% on serum specimens compared to MACRIA

To order contact BluePoint Bioscience
Catalog # MeVM010

Test Principle

In the Measles IgM capture EIA, diluted serum/plasma is added to anti-human IgM coated microtitre wells. IgM in the specimen binds to the wells and, after washing, recombinant measles nucleoprotein (rMVN) antigen is added. Measles specific IgM in the sample, if present, binds the rMVN. After washing the wells, a monoclonal antibody to the rMVN, conjugated to horseradish peroxidase is added to reveal the presence of measles specific IgM. After washing, tetramethylbenzidine (TMB) substrate is added. The presence of measles specific IgM in the sample results in a color change in the TMB from colorless to blue. The enzymatic reaction is terminated with acid, which causes further color change from blue to yellow. The color change and intensity are monitored using a spectrophotometric plate reader. The presence of measles specific IgM is indicated by optical density values above the cut-off.

